Hormonal

Unimolecular GLP-1/glucagon receptor co-agonists produce superior weight loss and metabolic improvements compared to GLP-1 mono-agonists by combining central satiety signaling with peripheral thermogenesis and lipolysis, while the GLP-1 component buffers the hyperglycemic risks of glucagon.

This research supports the use of GLP-1/glucagon co-agonists (like those currently in clinical trials or recently approved, e.g., tirzepatide, though this paper predates specific approvals) for treating obesity and type 2 diabetes. These drugs work by hitting two receptors: one to reduce appetite (GLP-1) and one to burn energy (Glucagon). The key advantage is that they are more effective than older GLP-1-only drugs (like liraglutide) and do not raise blood sugar, thanks to the balancing effect of the GLP-1 component. They are administered once weekly via injection. Patients should be aware of potential nausea, which is common but often manageable, and that long-term safety data is still being gathered.